Nutra Pharma has announced that they have engaged Pickwick Capital Partners to act as the Company's investment banking partner.
June 30, 2015 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Pickwick Capital Partners; a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services. Pickwick will focus on assisting Nutra Pharma in its strategies for maximizing shareholder value through its full scope of investment banking services.
"Nutra Pharma is in the process of managing growth as we expand the market for our OTC products," commented Rik J Deitsch, Chief Executive Officer of Nutra Pharma. "We recently announced our expansion into India and China. As our sales increase and the Company matures, we need strategic advisors to help navigate these waters, provide sound financial counseling and maximize the potential benefits to our customers and shareholders," he continued. "We are pleased to have retained a leading investment banking firm to assist the company with these important strategic decisions," he concluded.
Pickwick Capital Partners, LLC is a FINRA-Registered Broker Dealer and a Member of SIPC. They act as Strategic Advisors and Investment Bankers for a variety of corporate clients. In these capacities, they offer a full range of Business Development services and a complete array of transactional services for emerging and middle market corporate clients. Pickwick is also active in the placement of alternative asset Funds with institutional and accredited Investors.
"Pickwick Capital Partners is dedicated to creating real economic value for all of our clients and their stakeholders; investors, shareholders, management, and employees," stated Doug Greenwood, Chief Executive Officer of Pickwick Capital Partners. "We constantly seek to understand the objectives and needs of our clients, to provide superior services to them, and to earn their trust, respect, and confidence," he continued. "We are happy to be working with Nutra Pharma and helping them achieve their goals as they continue to grow," he concluded.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The engagement of Pickwick Cap[ital Partners should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.